Please fill out the form below and we will gladly respond as soon as possible.
Join the Synovial Sarcoma Foundation for a live, one-hour webinar focused on where synovial sarcoma research is heading and what that progress means for patients and families today. The conversation will bring together real patient experiences with insights from researchers and clinicians leading efforts in synovial sarcoma. We’ll discuss emerging research, areas of real momentum, […]
Zelluna, a Norway-based biotechnology company, has announced the submission of a Clinical Trial Application (CTA) in the United Kingdom for ZI-MA4-1 (ZIMA-101), a first-in-human cell therapy study that will include patients with synovial sarcoma. While this trial is still in its earliest phase, it represents a notable scientific development for the synovial sarcoma community. What […]
Current Patient to Drive Relationships and Support for the Synovial Sarcoma Community [Philadelphia, PA] – 12/12/25 – The Synovial Sarcoma Foundation (SSF) is thrilled to announce the appointment of Julie Kramer as our new Community Engagement & Partnerships Manager. With a wealth of experience in advocacy and nonprofit communications, and as a survivor of synovial […]
In a groundbreaking advancement in cancer treatment, a patient with synovial sarcoma in Arizona has become the first in the state to receive a cutting-edge immune-cell therapy, TECELRA, at the HonorHealth Research Institute in Scottsdale. Synovial sarcoma is a rare soft-tissue cancer that primarily affects large joints in the arms and legs, though it can […]
A landmark study just published in Nature Communications finally pinpointed the exact “cell of origin” for synovial sarcoma — a rare, primitive fibroblast that still carries embryonic markers (Hic1⁺ Pdgfra⁺ Lgr5⁺). Breaking 2025 Research: Read the entire article here. Learn more about our world-renowned registry efforts here.
The Synovial Sarcoma Foundation is excited to share that we are on site this week at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting in Boca Raton, Florida. This global event brings together leading researchers, oncologists, and experts in sarcoma to discuss the latest data-driven advancements in diagnosis, treatment, and clinical trials. Representing our Board of […]
The Synovial Sarcoma Foundation is pleased to highlight a significant milestone at the Children’s Hospital of Philadelphia (CHOP), where pediatric oncologist and Synovial Sarcoma Foundation Board Member, Dr. Theodore W. Laetsch, has been awarded a prestigious $1 million multi-year grant from the National Cancer Institute (NCI). This funding aims to accelerate research and treatment development […]
The Synovial Sarcoma Foundation is dedicated to supporting cutting-edge research that advances treatment options for this rare and aggressive cancer. Recent findings published in The EMBO Journal highlight a promising new strategy: using drug blockers to target a problematic protein involved in synovial sarcoma’s genetics. Synovial sarcoma primarily develops in soft tissues such as muscles […]
The Synovial Sarcoma Foundation is committed to staying informed on the latest research and developments in this rare and aggressive cancer. A recent market report indicates that the global synovial sarcoma market is projected to grow significantly, reaching an estimated USD 420 million by 2034 — up from USD 245 million in 2024, at a […]
We are proud to share that the Tumor Board now includes 42 participating institutions, strengthening our collective expertise and reach. These new members, along with our existing institutions, greatly enhance our ability to develop and implement cutting-edge, individualized treatment plans.